XML 44 R31.htm IDEA: XBRL DOCUMENT
v3.19.1

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions |  |  |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Aug. 29, 2017 | Jul. 06, 2016 | Jul. 07, 2014 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018
Co-development and license agreement |  |  |  |  |  |
Research and development expense |  |  |  | $ 11,606,197 | $ 8,449,267 |
Phase 3 Insomnia Trail |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Percentage of milestone payment on aggregate product development cost |  |  |  | 40.00% |  |
Janssen | Phase 3 Insomnia Trail |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Milestone method payments |  |  |  | $ 40,000,000 |  |
Janssen | Seltorexant | Co-Development and License Agreement |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Payment of license fee |  |  | $ 22,000,000 |  |  |
Payment of development costs |  | $ 3,500,000 |  |  |  |
Direct expenses incurred |  | $ 300,000 |  |  |  |
Research and development expense |  |  |  | $ 0 | $ 0 |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Upfront payment | $ 30,000,000 |  |  |  |  |
Revenue recognition, milestone method, factors |  |  |  | The $30 million payment and $11.2 million in previously accrued collaborative expenses, which were forgiven upon the effective date of the Amendment, are earned and recognized as revenue as the services are performed from the commencement of Phase 3 development to the completion of the development activities using the proportional performance method. |  |
Accrued collaborative expenses | 11,200,000 |  |  |  |  |
Upfront payment received |  |  |  | $ 30,000,000 |  | $ 30,000,000
Previously accrued collaborative expenses recognized as revenue |  |  |  | $ 11,200,000 |  | $ 11,200,000
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Payment start of Phase | 20,000,000 |  |  |  |  |
Payment upon enrollment of patients | $ 20,000,000 |  |  |  |  |
Percentage of patients to be enrolled | 50.00% |  |  |  |  |
Johnson & Johnson Innovation-JJDC Inc |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |
Stock repurchased | 3.9 |  |  |  |  |
Stock repurchased price per share | $ 0.0001 |  |  |  |  |
Aggregate purchase price | $ 389 |  |  |  |  |

X
- Definition Accrued research and development costs current. + References No definition available. + Details
Name: | nerv_AccruedResearchAndDevelopmentCostsCurrent
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contract with customer liability milestone method factors. + References No definition available. + Details
Name: | nerv_ContractWithCustomerLiabilityMilestoneMethodFactors
Namespace Prefix: | nerv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Direct expenses incurred, development costs. + References No definition available. + Details
Name: | nerv_DirectExpensesIncurredDevelopmentCosts
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of license fee. + References No definition available. + Details
Name: | nerv_PaymentOfLicenseFee
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for development cost. + References No definition available. + Details
Name: | nerv_PaymentsForDevelopmentCost
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of milestone payment on aggregate product development cost. + References No definition available. + Details
Name: | nerv_PercentageOfMilestonePaymentOnAggregateProductDevelopmentCost
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of patients to be enrolled. + References No definition available. + Details
Name: | nerv_PercentageOfPatientsToBeEnrolled
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product development cost payable. + References No definition available. + Details
Name: | nerv_ProductDevelopmentCostPayable
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product development cost payable upon enrollment of patients. + References No definition available. + Details
Name: | nerv_ProductDevelopmentCostPayableUponEnrollmentOfPatients
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue recognition milestone method revenue expected. + References No definition available. + Details
Name: | nerv_RevenueRecognitionMilestoneMethodRevenueExpected
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock repurchased price per share. + References No definition available. + Details
Name: | nerv_StockRepurchasedPricePerShare
Namespace Prefix: | nerv_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment paid. + References No definition available. + Details
Name: | nerv_UpfrontPaymentPaid
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12A -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL108322424-203045 + Details
Name: | us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseThreeClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nerv_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nerv_AmendmentToCoDevelopmentAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nerv_JohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |